tbuckley/cabot-search huggingface dataset:
CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells (Blood (2009) 113, 18, (4309-4318))
Authors: Y. T. Tai, E. Soydan, W. Song, M. Fulciniti, K. Kim, F. Hong, X. F. Li, P. Burger, M. J. Rumizen, S. Nahar, K. Podar, T. Hideshima, N. C. Munshi, G. Tonon, R. D. Carrasco, D. E.H. Afar, K. C. Anderson
Journal: Blood (2010)
The family practitioner as psychiatrist
Authors: A Feldman
Journal: American Journal of Psychiatry (1978)

The author describes attitudes held by nonpsychiatric physicians that are responsible for poor psychological handling of patients, including low interest in psychosocial aspects of illness, judgment of and disinterest in hypochondriasis or conversion reaction, avoidance of psychotic or terminally ill patients, and anger toward patients with unpleasant characteristics. He discusses reasons for these attitudes and suggests that medical schools increase psychological education and psychiatry departments increase the relevance of their teaching.
Errands
Authors: Andrew Bomback
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
A method for establishing reliability of statements from psychodynamic case formulations
Authors: S E Rosenberg, G Silberschatz, J T Curtis, H Sampson, J Weiss
Journal: American Journal of Psychiatry (1986)

The authors describe a method for assessing the reliability of statements derived from psychodynamic case formulations. By reducing a narrative formulation into a series of distinct statements and rating their relevance to a particular patient, they obtained good interjudge reliabilities.
Activity of neoadjuvant bevacizumab at the time of surgery after 6 weeks of preoperative cessation: A translational study.
Authors: Patrick Starlinger, Lejla Alidzanovic, Dominic Schauer, Thomas Maier, Silvia Sommerfeldt, Beata Perisanidis, Dietmar Tamandl, Birgit Gruenberger, Thomas Gruenberger, Christine Brostjan
Journal: Journal of Clinical Oncology (2012)

e14099 Background: The use of bevacizumab (BV), a monoclonal antibody against VEGF, together with an increase in hepatic resection has improved the outcome of colorectal cancer (CRC) patients with liver metastasis. However, despite the frequent use of BV, its accurate timing prior to liver resection to avoid surgical complications and to allow for hepatic regeneration remains discussed controversially. In this context, it is unclear to which extent VEGF is complexed by BV at the time of surgery. Methods: 42 CRC patients with liver metastases, potentially curable by resection, were included. Patients received neoadjuvant chemotherapy (CTx) either with or without concomitant biweekly BV. The last cycle of therapy did not include BV, resulting in a median 6 weeks between the last administration of BV and surgery. Plasma and wound fluid were obtained perioperatively. Immunoprecipitation was applied to determine the proportion of BV-bound VEGF. Alternative angiogenesis factors were evaluated. Results: No increased perioperative complications in BV treated patients were observed. At the time of surgery, the majority of plasma VEGF was inactivated by BV. In wound fluid, the actual site of wound healing and hepatic regeneration, VEGF was remarkably low and also complexed by BV. The anti-angiogenic protein thrombospondin-1 was reduced in BV treated patients. Conclusions: These data document that after the clinical standard cessation time of 6 weeks, BV is still fully active and binds to the majority of circulating and local (wound fluid) VEGF. Despite the potent VEGF inactivation at the time of liver resection no substantial increase in perioperative morbidity after neoadjuvant BV therapy has been documented in our study and the current literature. Compensatory mechanisms, such as thrombospondin-1 reduction during BV treatment may enable wound healing.
Development of FF-10101, a Novel Irreversible FLT3 Inhibitor, Which Overcomes Drug Resistance Mutations
Authors: Toshiyuki Nakatani, Ken Uda, Takeshi Yamaura, Masaru Takasaki, Akimi Akashi, Fangli Chen, Yuichi Ishikawa, Fumihiko Hayakawa, Shinji Hagiwara, Hitoshi Kiyoi, Tomoki Naoe
Journal: Blood (2015)
Parents of children having heart surgery at Bristol hospital “were let down”
Authors: Clare Dyer
Journal: BMJ (2016)

Babies and children who were treated for congenital heart problems at Bristol Royal Hospital for Children were put at “a clear risk of harm” on a ward staffed by too few nurses, an independent review has concluded.1

Bruce Keogh, medical director of NHS England, set up the “Bristol Review,” chaired by Eleanor Grey QC, to consider the safety and quality of children’s cardiac services in Bristol from March 2010. The review was launched in June 2014 after pressure from parents who believed that their children may have died unnecessarily after treatment at the hospital.

A large percentage of the patients on ward 32, to which children were admitted from intensive …
Performance of a biomarker panel to identify malignancy within a pelvic mass population
Authors: L. Chen, H. D. Homesley, D. R. Scribner, G. H. Cantuaria, Q. He, R. L. Cheek, C. M. Whitehead, H. Doobay, T. J. Fischer
Journal: Journal of Clinical Oncology (2009)

5566 Background: We previously reported the performance of biomarker combinations that displayed utility in identifying ovarian cancer from normal sera and in monitoring for disease recurrence. In this study, we evaluated the performance of a subset of these markers in differentiating ovarian cancer from benign pelvic mass. Methods: Pre-operative serum samples were prospectively collected from 254 patients undergoing surgical evaluation for differential diagnosis of a pelvic mass. Pathology showed 76 cases of epithelial ovarian carcinoma (EOC), 17 borderline tumors, 11 other gynecologic cancers, and 150 benign masses. 18 (23.7%) of the EOC patients had stage I tumors; 6 (7.9%) stage II; 44 (57.9%) stage III; and 8 (10.5%) stage IV. Serum levels of CA125, HE4, glycodelin, SLPI, MMP7, and Plau-R were ascertained. Biomarker performance was evaluated by a logistic regression model and leave one out cross-validation analysis. All calculations compared the benign vs. EOC and borderline tumor populations. Results: Individual biomarker sensitivity ranged from 28% to 77% at 85% specificity. The combination of CA125, HE4 and glycodelin exhibited the highest overall performance in identifying malignancy from benign masses, demonstrating 80% sensitivity, 80% specificity in patients &lt;55 years, and 89% sensitivity, 80% specificity in patients ≥55. Total cohort performance was 85% sensitivity and 80% specificity. Glycodelin identified 7/22 CA125 and HE4 double negative patients, 5/7 of these patients were early stage (borderline, I or II), while only adding 4/150 false positive cases. Conclusions: Biomarker analysis within this test cohort demonstrates potential clinical utility in the differential diagnosis of pelvic mass patients, especially for the detection of early stage disease. The addition of glycodelin improved the detection of early stage cancer in sera that were negative for both HE4 and CA125. [Table: see text]
FC-gamma receptor IIIA (FCGR3A) polymorphism and DFS in follicular lymphoma patients after idiotype vaccination in first remission.
Authors: M. A. Popa-Mckiver, A. M. McCord, S. S. Neelapu, C. F. Santos
Journal: Journal of Clinical Oncology (2010)

e13125 Background: FCGR3A (CD16) polymorphisms affect the affinity of macrophages and NK cells to bind IgG1 and thus mediate ADCC. The FCGR3A-158-V allotype is reportedly associated with better response rates after rituximab therapy and longer progression-free survival after idiotype (Id) vaccination as compared to the 158-F allotype in follicular lymphoma patients (FL). We previously reported prolonged disease-free survival (DFS) in patients receiving vaccination with autologous tumor-derived Id conjugated to keyhole limpet hemocyanin (KLH) administered with GM-CSF as compared to patients receiving KLH control with GM-CSF. However, the underlying mechanism of the antitumor effect remains unknown. Methods: The objective of this study was to evaluate the prognostic significance of FCGR3A polymorphisms resulting in an amino acid substitution at position 158 in FL patients from the randomized, double-blind BV301trial who received active Id-KLH (N=75) or KLH control (N= 41) vaccine after achieving complete remission or complete remission unconfirmed with PACE chemotherapy. The primary endpoint of this study was DFS from randomization after chemotherapy response assessment. Results: The genotype distribution included 44% F/F, 48% F/V, 8% V/V in the Id-KLH arm, and 44% F/F, 41% F/V, 15% V/V in the KLH arm. There were no statistically significant differences in demographics, clinical and histologic features, and number of PACE cycles received among the 3 genotype groups or between study arms. Median DFS estimates by 3 genotype groups within the Id-KLH arm were not significantly different (38.5 mo F/F, 46.0 mo V/F, 40.2 mo V/V, p= 0.543). Median DFS estimates between the V carriers (V/V and F/V) and F/F genotypes within the Id-KLH arm were not significantly different (44.2 mo vs. 38.5 mo, p=0.448). Comparisons between the Id- KLH and KLH arm suggest a trend toward better DFS in the Id-KLH arm in all V carriers (44.2 vs. 26.2mo, p= 0.069) but not in F/F genotypes. Conclusions: Our results suggest that polymorphisms in FCGR3A do not have prognostic value in FL patients treated with Id-KLH vaccination. However, our small sample size may preclude the identification of significant results. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Biovest International, Inc. Biovest International, Inc. Biovest International, Inc.
Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries
Authors: S. Kleijnen, I. Lipska, T. Leonardo Alves, K. Meijboom, A. Elsada, V. Vervölgyi, A. d'Andon, A. Timoney, H.G. Leufkens, A. De Boer, W.G. Goettsch
Journal: Annals of Oncology (2016)
Psychosomatic Aspects of Patients on Hemodialysis
Authors: I Fukunishi
Journal: Psychotherapy and Psychosomatics (1989)

Psychosomatic aspects of aged dialysis patients, who had been on long-term dialysis and started on dialysis at over 65 years old, were examined using various psychological tests such as MMPI Alexithymia Scale and Beth Israel Questionnaire. Alexithymic trait was observed most frequently in aged long-term dialysis patients. This trait has a correlation with physical complications, patients having bone or joint disturbance. From these results, two different alexithymic patterns are inferred: (1) Because of poor awareness concerning control of their own body, physical complications develop in patients with a predisposition for alexithymia, and (2) physical complications inevitably occur during long-term dialysis and patients exhibit secondary alexithymia.
The Otoscope
Authors: Anisa K Moore
Journal: JAMA (2006)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Platinum-based chemotherapy (CT) plus cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck cancer (R/M-SCCHN): 5-year follow-up data for the extreme trial.
Authors: Jan Baptist Vermorken, Eva Remenar, Ricardo Hitt, Andrzej Kawecki, Sylvie Rottey, Luise Knierim, Jeltje Schulten, Ricard Mesia
Journal: Journal of Clinical Oncology (2014)

6021^ Background: The EXTREME trial demonstrated that patients with R/M-SCCHN benefit significantly from the addition of cetuximab to first-line platinum-based CT in relation to overall survival, progression-free survival (PFS) and response rate. We report the 5-year follow-up data. Methods: The intent-to-treat (ITT) population comprised patients (pts) randomized to receive either platinum-based CT plus cetuximab (n=222) or CT alone (n=220) for 18 weeks (6 x 3-week cycles). Results: A total of 100 pts in the cetuximab arm who had at least stable disease received cetuximab monotherapy until disease progression or unacceptable toxicity, with a median treatment duration of 29.9 weeks. For 77% of these pts, the relative dose intensity (RDI) of cetuximab was ≥90% during this maintenance period. Thirty-one (14%) pts in the cetuximab arm and 25 (11%) in the CT arm of the ITT population were deemed long-term survivors (>2 years). Of these, 6 (22%) and 5 (23%) pts were p16+ and 11 (35%) and 10 (40%) pts had oropharyngeal tumors, in both arms respectively. At 5-years, 6 pts treated with CT plus cetuximab and 2 pts treated with CT alone were still in the study and known to be alive. In pts in the cetuximab arm, the frequency of severe (grade 3-4) adverse events (AEs) decreased from 81% to 49% during the cetuximab maintenance period compared with the previous treatment period with CT plus cetuximab. Grade 3 skin toxicity decreased from 9% when combined with CT to 5% during cetuximab maintenance and no grade 4 skin toxicity was observed.Twelve pts (5%) in the cetuximab arm of the ITT population were long-term responders (PFS>12 months) compared with 3 pts (1%) in the CT arm, with a median treatment duration of 67.7 weeks. The RDI of cetuximab was ≥90% for all long-term responders. Conclusions: The addition of cetuximab to first-line platinum-based CT significantly improves outcome for patients with R/M-SCCHN. Although there are notable differences in long-term responders favoring cetuximab, the 5-year survival figures are still extremely low for both arms of the study. Cetuximab maintenance therapy proved to be feasible with manageable skin reactions. Clinical trial information: NCT00122460.
포스터 발표 : 만성 간염 및 간경변증 환자에서 원인에 따른 혈청 Iron parameter의 변화
Authors: 조용균, 김병익, 윤중원, 김정욱, 박동일, 성인경, 박창영, 손정일, 전우규
Journal: Clinical and Molecular Hepatology (2003)

배경/목적: 철분과잉 상태는 간염바이러스 및 알코올에 의한 만성간염에서 질환의 경과 및 치료효과에 악영향을 미치고 간손상을 유발하는 요인으로 작용한다. 본 연구의 목적은 만성 바이러스성 간염(HBV, HCV), 만성 알코올성 간염 환자 및 간경변증 환자에 있어서의 혈중 철대사에 관계되는 여러 지표를 비교하여 간세포 손상에 어떠한 영향을 미치는지 알고자 하였다. 대상과 방법: 각종 감염성 질환, 혈액질환 환자를 제외한 총 60명의 만성간염(HBV: 31명, HCV: 19명, 알코올성: 10명) 환자와 비대상성 간경변증을 제외한 총 47명의 간경변증 환자(HBV: 29명, HCV: 8명, 알코올성: 10명)를 대상으로 혈청내 Iron, Ferritin, TIBC농도를 측정하여 각 군간 간질환의 원인에 따라 의의있는 차이가 있는지 분석하였으며 이러한 지표와 간손상의 정도를 반영하는 혈청 간기능 지표와의 상관관계를 알아보고자 하였다. 결과: 만성 간염군과 간경변증군에서의 성별, 연령별 차이는 없었다. 간경변 환자군에서 만성 간염군에 비해 Ferritin 농도가 의의있게 높게 관찰되었으며(167.9±15.6, 125.5±12.6 ug/L, p＜0.05) 반면 TIBC는 낮게 측정되었다(284.7±48.7, 337.5±79.8 ug/dL p＜0.05). 각 군간 원인에 따른 분석에서 알코올성 간염의 경우 혈청 Iron 농도 147.9±33.5 ug/dL로 각각 만성 B형 및 만성 C형 간염환자 122.5±14.6, 125.5±15.2 ug/dL에 비해 증가된 소견을 보였고(p＜0.05) Ferritin 농도 또한 알코올성 간염의 경우 만성 B형 및 만성 C형 간염환자에 비해 증가되었다.(154.5±19.8 Vs 114.5±11.5, 120.5±14.7 ug/L, p＜0.05). 간경변증군에서는 알코올성의 경우 혈청 Iron 농도 159.5±68.9ug/dl로 B형 및 C형 간염에 의한 간경변증환자 132.8±35.7, 129.7±22.7 ug/dL에 비해 증가된 소견을 보였고(p＜0.05) Ferritin 농도 역시 증가된 소견을 보였다(189.4±89.4 Vs 148.7±54.5, 155.4±59.6 ug/L, p＜0.05). 그러나 TIBC는 원인에 따른 각 군간 의의있는 차이가 없었다. 만성간염 환자군에서 혈청 Ferritin과 ALT 및 GGT 값이 의의있는 양의 상관관계를 보였으며 만성 B형 및 C형 간염에 비해 특히 알코올성 간염에서 의의있게 나타났다(r＝0.612, r＝0.743 p＜0.001). 결론: Iron parameter는 각종 간질환의 원인에 따라 다르게 관찰되었다. 철분 과잉상태는 알코올성 간질환에서 다른 원인에 비해 의의있게 관찰되었고 혈청 Ferritin 값이 간손상의 지표로 작용할수 있음을 시사하였다.
Feasibility of Deploying Inhaler Sensors to Identify the Impacts of Environmental Triggers and Built Environment Factors on Asthma Short-Acting Bronchodilator Use
Authors: Jason G. Su, Meredith A. Barrett, Kelly Henderson, Olivier Humblet, Ted Smith, James W. Sublett, LaQuandra Nesbitt, Chris Hogg, David Van Sickle, James L. Sublett
Journal: Environmental Health Perspectives (2016)

Epidemiological asthma research has relied upon self-reported symptoms or healthcare utilization data, and used the residential address as the primary location for exposure. These data sources can be temporally limited, spatially aggregated, subjective, and burdensome for the patient to collect.First, we aimed to test the feasibility of collecting rescue inhaler use data in space-time using electronic sensors. Second, we aimed to evaluate whether these data have the potential to identify environmental triggers and built environment factors associated with rescue inhaler use and to determine whether these findings would be consistent with the existing literature.We utilized zero-truncated negative binomial models to identify triggers associated with inhaler use, and implemented three sensitivity analyses to validate our findings.Electronic sensors fitted on metered dose inhalers tracked 5,660 rescue inhaler use events in space and time for 140 participants from 13 June 2012 to 28 February 2014. We found that the inhaler sensors were feasible in passively collecting objective rescue inhaler use data. We identified several environmental triggers with a positive and significant association with inhaler use, including: AQI, PM10, weed pollen, and mold. Conversely, the spatial distribution of tree cover demonstrated a negative and significant association with inhaler use.Utilizing a sensor to capture the signal of rescue inhaler use in space-time offered a passive and objective signal of asthma activity. This approach enabled detailed analyses to identify environmental triggers and built environment factors that are associated with asthma symptoms beyond the residential address. The application of these new technologies has the potential to improve our surveillance and understanding of asthma. Citation: Su JG, Barrett MA, Henderson K, Humblet O, Smith T, Sublett JW, Nesbitt L, Hogg C, Van Sickle D, Sublett JL. 2017. Feasibility of deploying inhaler sensors to identify the impacts of environmental triggers and built environment factors on asthma short-acting bronchodilator use. Environ Health Perspect 125:254-261; http://dx.doi.org/10.1289/EHP266.
Characterization of Mentorship Programs in Departments of Surgery in the United States
Authors: Melina R. Kibbe, Carlos A. Pellegrini, Courtney M. Townsend, Irene B. Helenowski, Marco G. Patti
Journal: JAMA Surgery (2016)

Mentorship is considered a key element for career satisfaction and retention in academic surgery. Stakeholders of an effective mentorship program should include the mentor, the mentee, the department, and the institution.The objective of this study was to characterize the status of mentorship programs in departments of surgery in the United States, including the roles of all 4 key stakeholders, because to our knowledge, this has never been done.A survey was sent to 155 chairs of departments of surgery in the United States in July 2014 regarding the presence and structure of the mentorship program in their department. The analysis of the data was performed in November 2014 and December 2014.Presence and structure of a mentorship program and involvement of the 4 key stakeholders.Seventy-six of 155 chairs responded to the survey, resulting in a 49% response rate. Forty-one of 76 of department chairs (54%) self-reported having an established mentorship program. Twenty-five of 76 departments (33%) described no formal or informal pairing of mentors with mentees. In 62 (82%) and 59 (78%) departments, no formal training existed for mentors or mentees, respectively. In 42 departments (55%), there was no formal requirement for the frequency of scheduled meetings between the mentor and mentee. In most departments, mentors and mentees were not required to fill out evaluation forms, but when they did, 28 of 31 were reviewed by the chair (90%). In 70 departments (92%), no exit strategy existed for failed mentor-mentee relationships. In more than two-thirds of departments, faculty mentoring efforts were not recognized formally by either the department or the institution, and only 2 departments (3%) received economic support for the mentoring program from the institution.These data show that only half of departments of surgery in the United States have established mentorship programs, and most are informal, unstructured, and do not involve all of the key stakeholders. Given the importance of mentorship to career satisfaction and retention, development of formal mentorship programs should be considered for all academic departments of surgery.
Prediction of reproductive status in women with bulimia nervosa by past high weight
Authors: T E Weltzin, J Cameron, S Berga, W H Kaye
Journal: American Journal of Psychiatry (1994)

It is not understood why disturbed menstrual function occurs in as many as 50% of women with bulimia nervosa who are at normal weight. The authors measured luteinizing hormone (LH), estradiol, and progesterone in 13 women with bulimia nervosa who were at normal weight and six normal comparison subjects. They found that the women with bulimia nervosa were likely to have abnormal 24-hour luteinizing hormone (LH) secretion if their current weight was less than 85% of their past high weight.